|
Powered by Cell Signaling Technology |
Site Information |
---|
rtkQtArkstGGkAP SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 463820 |
Available spectra: 3 CST |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Regulatory protein: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on H3: | |
Effects of modification on biological processes: | |
Induce interaction with: | |
Inhibit interaction with: |
Disease / Diagnostics Relevance | |
---|---|
Relevant diseases: |
References | |
---|---|
Ko HJ, et al. (2022) BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death. Cell Commun Signal 20, 200
36575468 Curated Info |
|
Song H, et al. (2022) NFκB induces epigenetic repression of GPRC5A in lung epithelial cells to promote neoplasia. JCI Insight
36413416 Curated Info |
|
Zhang Q, et al. (2022) Deficiency of p53 Causes the Inadequate Expression of miR-1246 in B Cells of Systemic Lupus Erythematosus. J Immunol 209, 1492-1498
36165173 Curated Info |
|
Neudorf H, Jackson G, Little JP (2022) Examining the Effect of Consuming C Medium-Chain Triglyceride Oil for 14 Days on Markers of NLRP3 Activation in Healthy Humans. J Nutr Metab 2022, 7672759
35433045 Curated Info |
|
Lee M, et al. (2022) Adipocyte-mediated epigenomic instability in human T-ALL cells is cytotoxic and phenocopied by epigenetic-modifying drugs. Front Cell Dev Biol 10, 909557
36060800 Curated Info |
|
Bompada P, et al. (2021) Epigenome-Wide Histone Acetylation Changes in Peripheral Blood Mononuclear Cells in Patients with Type 2 Diabetes and Atherosclerotic Disease. Biomedicines 9
34944721 Curated Info |
|
Yang PB, et al. (2020) Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression. Proc Natl Acad Sci U S A 117, 27412-27422
33087562 Curated Info |
|
Ge M, et al. (2020) Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. Oncogene 39, 5888-5901
32733069 Curated Info |
|
Peng L, et al. (2020) Deacetylase-independent function of SIRT6 couples GATA4 transcription factor and epigenetic activation against cardiomyocyte apoptosis. Nucleic Acids Res 48, 4992-5005
32239217 Curated Info |
|
Yu Z, et al. (2020) The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically. Oncogene 39, 3163-3178
32051553 Curated Info |
|
Yu Y, et al. (2020) RBBP8/CtIP suppresses P21 expression by interacting with CtBP and BRCA1 in gastric cancer. Oncogene 39, 1273-1289
31636387 Curated Info |
|
Karkhanis V, et al. (2020) Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. J Biol Chem 295, 1165-1180
31822509 Curated Info |
|
Lin HH, et al. (2020) Overexpression of FAM46A, a Non-canonical Poly(A) Polymerase, Promotes Hemin-Induced Hemoglobinization in K562 Cells. Front Cell Dev Biol 8, 414
32528962 Curated Info |
|
Jung JH, et al. (2019) Farnesiferol C Induces Apoptosis in Chronic Myelogenous Leukemia Cells as an Imatinib Sensitizer via Caspase Activation and HDAC (Histone Deacetylase) Inactivation. Int J Mol Sci 20
31698777 Curated Info |
|
Gruber JJ, et al. (2019) HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding. Mol Cell 75, 711-724.e5
31278053 Curated Info |
|
Chen SH, et al. (2019) HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells. Int J Mol Sci 20
31071955 Curated Info |
|
Márquez S, et al. (2019) Tricarboxylic Acid Cycle Activity and Remodeling of Glycerophosphocholine Lipids Support Cytokine Induction in Response to Fungal Patterns. Cell Rep 27, 525-536.e4
30970255 Curated Info |
|
Srinivasan S, Shankar SR, Wang Y, Taneja R (2019) SUMOylation of G9a regulates its function as an activator of myoblast proliferation. Cell Death Dis 10, 250
30867409 Curated Info |
|
Deng R, et al. (2018) HDAC is indispensable for IFN-¿¿-induced B7-H1 expression in gastric cancer. Clin Epigenetics
30537988 Curated Info |
|
Guo H, et al. (2018) Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene
30361685 Curated Info |
|
Surapaneni SK, Bashir S, Tikoo K (2018) Gold nanoparticles-induced cytotoxicity in triple negative breast cancer involves different epigenetic alterations depending upon the surface charge. Sci Rep
30115982 Curated Info |
|
Li X, et al. (2018) Heritable, Allele-Specific Chromosomal Looping between Tandem Promoters Specifies Promoter Usage of SHC1. Mol Cell Biol
29440311 Curated Info |
|
Wu Y, et al. (2018) Regulatory Roles of Histone Deacetylases 1 and 2 in Pb-induced Neurotoxicity. Toxicol Sci
29301062 Curated Info |
|
Lee JH, et al. (2017) Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. ACS Chem Biol 12, 2804-2814
28949514 Curated Info |
|
Zhu Q, et al. (2017) Human CRL4DDB2 ubiquitin ligase preferentially regulates post-repair chromatin restoration of H3K56Ac through recruitment of histone chaperon CAF-1. Oncotarget
29262658 Curated Info |
|
Lasko LM, et al. (2017) Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 550, 128-132
28953875 Curated Info |
|
Hideshima T, et al. (2017) HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget 8
29113288 Curated Info |
|
Zhao Y, et al. (2017) Induction of reprogramming of human amniotic epithelial cells into iPS cells by overexpression of Yap, Oct4, and Sox2 through the activation of the Hippo-Yap pathway. Exp Ther Med 14, 199-206
28672915 Curated Info |
|
Gatla HR, et al. (2017) Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. J Biol Chem 292, 5043-5054
28167529 Curated Info |
|
Ferreira RC, et al. (2016) Histone Deacetylase 1 Is Essential for Rod Photoreceptor Differentiation by Regulating Acetylation at Histone H3 Lysine 9 and Histone H4 Lysine 12 in the Mouse Retina. J Biol Chem
28028172 Curated Info |
|
Wang L, et al. (2016) Activin/Smad2-induced Histone H3 Lys-27 Trimethylation (H3K27me3) Reduction Is Crucial to Initiate Mesendoderm Differentiation of Human Embryonic Stem Cells. J Biol Chem
27965357 Curated Info |
|
Corbet C, et al. (2016) Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation. Cell Metab 24, 311-23
27508876 Curated Info |
|
Fischer N, et al. (2016) Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge. Proc Natl Acad Sci U S A 113, E2993-3001
27162363 Curated Info |
|
Noguchi S, et al. (2015) Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition. Lung 193, 691-700
26286207 Curated Info |
|
Renneville A, et al. (2015) EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood 126, 1930-9
26320100 Curated Info |
|
Sidoli S, et al. (2015) Sequential Window Acquisition of all Theoretical Mass Spectra (SWATH) Analysis for Characterization and Quantification of Histone Post-translational Modifications. Mol Cell Proteomics 14, 2420-8
25636311 Curated Info |
|
Sociali G, et al. (2015) Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. Eur J Med Chem 102, 530-9
26310895 Curated Info |
|
Liu S, et al. (2015) G9a is essential for EMT-mediated metastasis and maintenance of cancer stem cell-like characters in head and neck squamous cell carcinoma. Oncotarget 6, 6887-901
25749385 Curated Info |
|
Johnson DP, et al. (2015) HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget 6, 4863-87
25605023 Curated Info |
|
Di Stefano V, et al. (2015) RelB/p52-mediated NF-κB signaling alters histone acetylation to increase the abundance of corticotropin-releasing hormone in human placenta. Sci Signal 8, ra85
26307012 Curated Info |
|
Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520
25825284 Curated Info |
|
Xing Z, et al. (2014) lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals. Cell 159, 1110-25
25416949 Curated Info |
|
Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113 Curated Info |
|
Jiang Y, et al. (2014) PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell 53, 75-87
24316223 Curated Info |
|
Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790 Curated Info |
|
Zhong Q, Kowluru RA (2013) Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 62, 2559-68
23423566 Curated Info |
|
Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302 Curated Info |
|
Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Arteaga MF, et al. (2013) The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell 23, 376-89
23518351 Curated Info |
|
Wu SY, et al. (2013) Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell 49, 843-57
23317504 Curated Info |
|
Webster SJ, et al. (2013) Regulation of GTP-binding Protein (Gαs) Expression in Human Myometrial Cells: A ROLE FOR TUMOR NECROSIS FACTOR IN MODULATING Gαs PROMOTER ACETYLATION BY TRANSCRIPTIONAL COMPLEXES. J Biol Chem 288, 6704-16
23297421 Curated Info |
|
Nair SS, Li DQ, Kumar R (2013) A Core Chromatin Remodeling Factor Instructs Global Chromatin Signaling through Multivalent Reading of Nucleosome Codes. Mol Cell 49, 704-18
23352453 Curated Info |
|
Dovey OM, et al. (2013) Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood 121, 1335-44
23287868 Curated Info |
|
Kuo YM, Andrews AJ (2013) Quantitating the specificity and selectivity of gcn5-mediated acetylation of histone h3. PLoS One 8, e54896
23437046 Curated Info |
|
Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Du W, et al. (2012) The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood 119, 4142-51
22408259 Curated Info |
|
Mannava S, et al. (2012) KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119, 1450-8
22144178 Curated Info |
|
Agricola E, et al. (2011) Recruitment of TIF1γ to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 43, 85-96
21726812 Curated Info |
|
Ishiguro K, et al. (2011) Cutting edge: tubulin α functions as an adaptor in NFAT-importin β interaction. J Immunol 186, 2710-3
21278340 Curated Info |
|
Guo R, Chen J, Mitchell DL, Johnson DG (2011) GCN5 and E2F1 stimulate nucleotide excision repair by promoting H3K9 acetylation at sites of damage. Nucleic Acids Res 39, 1390-7
20972224 Curated Info |
|
Gomez D, et al. (2011) Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res 89, 446-56
20829218 Curated Info |
|
Kim H, Jang MJ, Kang MJ, Han YM (2011) Epigenetic signatures and temporal expression of lineage-specific genes in hESCs during differentiation to hepatocytes in vitro. Hum Mol Genet 20, 401-12
21059703 Curated Info |
|
Aguilera C, et al. (2011) c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature 469, 231-5
21196933 Curated Info |
|
Huang PH, et al. (2011) Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol 79, 197-206
20959362 Curated Info |
|
Sakabe K, Hart GW (2010) O-GlcNAc transferase regulates mitotic chromatin dynamics. J Biol Chem 285, 34460-8
20805223 Curated Info |
|
Szerlong HJ, Prenni JE, Nyborg JK, Hansen JC (2010) Activator-dependent p300 acetylation of chromatin in vitro: enhancement of transcription by disruption of repressive nucleosome-nucleosome interactions. J Biol Chem 285, 31954-64
20720004 Curated Info |
|
Plazas-Mayorca MD, et al. (2010) Quantitative proteomics reveals direct and indirect alterations in the histone code following methyltransferase knockdown. Mol Biosyst 6, 1719-29
20577673 Curated Info |
|
Gaub P, et al. (2010) HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF-dependent p53 acetylation. Cell Death Differ 17, 1392-408
20094059 Curated Info |
|
Li Y (2010) CST Curation Set: 10374; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10376; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10388; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10380; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10383; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10377; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10375; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10399; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10392; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10379; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10381; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10396; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10395; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10387; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10397; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10386; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10378; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10382; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10385; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10384; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10394; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10373; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Nakata Y, et al. (2010) c-Myb, Menin, GATA-3, and MLL form a dynamic transcription complex that plays a pivotal role in human T helper type 2 cell development. Blood 116, 1280-90
20484083 Curated Info |
|
Li Y (2010) CST Curation Set: 10350; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10329; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10338; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10341; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10326; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10344; Year: 2010; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10327; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10339; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10334; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10322; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10348; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10337; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10323; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10349; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10340; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10332; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10320; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10330; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10333; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10360; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10354; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10356; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2010) CST Curation Set: 10353; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Tucker M (2010) CST Curation Set: 10224; Year: 2010; Biosample/Treatment: cell line, Reh/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Darwanto A, et al. (2010) A modified "cross-talk" between histone H2B Lys-120 ubiquitination and H3 Lys-79 methylation. J Biol Chem 285, 21868-76
20442396 Curated Info |
|
Gordon JA, et al. (2010) Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors. Mol Cell Biol 30, 3531-41
20439491 Curated Info |
|
Jiang X, Xu Y, Price BD (2010) Acetylation of H2AX on lysine 36 plays a key role in the DNA double-strand break repair pathway. FEBS Lett 584, 2926-30
20488183 Curated Info |
|
Moritz A (2010) CST Curation Set: 9922; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9919; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9921; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9820; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9823; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2010) CST Curation Set: 9819; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9822; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Horáková AH, et al. (2010) SUV39h-independent association of HP1 beta with fibrillarin-positive nucleolar regions. Chromosoma 119, 227-41
20033197 Curated Info |
|
Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2010) CST Curation Set: 9794; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Lee HS, et al. (2010) A cooperative activation loop among SWI/SNF, gamma-H2AX and H3 acetylation for DNA double-strand break repair. EMBO J 29, 1434-45
20224553 Curated Info |
|
Zhou LX, et al. (2010) Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy. Asian J Androl 12, 171-9
19935671 Curated Info |
|
Das C, Gadad SS, Kundu TK (2010) Human positive coactivator 4 controls heterochromatinization and silencing of neural gene expression by interacting with REST/NRSF and CoREST. J Mol Biol 397, 1-12
20080105 Curated Info |
|
Li X, et al. (2010) H4R3 methylation facilitates beta-globin transcription by regulating histone acetyltransferase binding and H3 acetylation. Blood 115, 2028-37
20068219 Curated Info |
|
Paakinaho V, Makkonen H, Jääskeläinen T, Palvimo JJ (2010) Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol Endocrinol 24, 511-25
20093418 Curated Info |
|
Vlaicu SI, et al. (2010) Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol 88, 67-76
19883641 Curated Info |
|
Davies GF, et al. (2010) Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett 288, 236-50
19699029 Curated Info |
|
Possemato A (2010) CST Curation Set: 8997; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4
20167786 Curated Info |
|
Martens JH, et al. (2010) PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 17, 173-185
20159609 Curated Info |
|
I H, et al. (2010) Association of global levels of histone modifications with recurrence-free survival in stage IIB and III esophageal squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 19, 566-73
20142251 Curated Info |
|
Inamochi Y, et al. (2010) Histone H3 methylation at lysine 4 on the SLC2A5 gene in intestinal Caco-2 cells is involved in SLC2A5 expression. Biochem Biophys Res Commun 392, 16-21
20043883 Curated Info |
|
Dufau ML, Liao M, Zhang Y (2010) Participation of signaling pathways in the derepression of luteinizing hormone receptor transcription. Mol Cell Endocrinol 314, 221-7
19464346 Curated Info |
|
Tucker M (2010) CST Curation Set: 8956; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Tucker M (2010) CST Curation Set: 8955; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Tucker M (2010) CST Curation Set: 8953; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Tucker M (2010) CST Curation Set: 8952; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Tucker M (2010) CST Curation Set: 8951; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Wurdak H, et al. (2010) An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 6, 37-47
20085741 Curated Info |
|
Calero-Nieto FJ, Bert AG, Cockerill PN (2010) Transcription-dependent silencing of inducible convergent transgenes in transgenic mice. Epigenetics Chromatin 3, 3
20180972 Curated Info |
|
Moritz A (2009) CST Curation Set: 8728; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2009) CST Curation Set: 8730; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2009) CST Curation Set: 8729; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2009) CST Curation Set: 8727; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
McGee SL, Fairlie E, Garnham AP, Hargreaves M (2009) Exercise-induced histone modifications in human skeletal muscle. J Physiol 587, 5951-8
19884317 Curated Info |
|
Cang S, et al. (2009) Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells. Int J Oncol 35, 1417-22
19885564 Curated Info |
|
Meng CF, Zhu XJ, Peng G, Dai DQ (2009) Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells. Oncol Rep 22, 1221-7
19787243 Curated Info |
|
Musselman CA, et al. (2009) Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem J 423, 179-87
19624289 Curated Info |
|
Moritz A (2009) CST Curation Set: 7940; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2009) CST Curation Set: 7941; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Ravindra KC, et al. (2009) Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. J Biol Chem 284, 24453-64
19570987 Curated Info |
|
Hinshelwood RA, et al. (2009) Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum Mol Genet 18, 3098-109
19477956 Curated Info |
|
Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861 Curated Info |
|
Zhou Y, et al. (2009) Reversible acetylation of the chromatin remodelling complex NoRC is required for non-coding RNA-dependent silencing. Nat Cell Biol 11, 1010-6
19578370 Curated Info |
|
Strasák L, et al. (2009) H3K9 acetylation and radial chromatin positioning. J Cell Physiol 220, 91-101
19248079 Curated Info |
|
Umezawa R, et al. (2009) Aberrant histone modifications at the thyrotropin-releasing hormone gene in resistance to thyroid hormone: analysis of F455S mutant thyroid hormone receptor. Endocrinology 150, 3425-32
19299458 Curated Info |
|
Tjeertes JV, Miller KM, Jackson SP (2009) Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J 28, 1878-89
19407812 Curated Info |
|
Paradowska A, et al. (2009) Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. Int J Oncol 35, 87-96
19513555 Curated Info |
|
Araki Y, et al. (2009) Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 30, 912-25
19523850 Curated Info |
|
Wang D, et al. (2009) Negative regulation of TSHalpha target gene by thyroid hormone involves histone acetylation and corepressor complex dissociation. Mol Endocrinol 23, 600-9
19196836 Curated Info |
|
Chan DW, et al. (2009) Unbiased proteomic screen for binding proteins to modified lysines on histone H3. Proteomics 9, 2343-54
19337993 Curated Info |
|
Li Y (2009) CST Curation Set: 6526; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6528; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6527; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6522; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6525; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6521; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6524; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6520; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6514; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6513; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6511; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6509; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6510; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2009) CST Curation Set: 6512; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Southall SM, et al. (2009) Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell 33, 181-91
19187761 Curated Info |
|
Akan P, Sahlén M, Deloukas P (2009) A histone map of human chromosome 20q13.12. PLoS One 4, e4479
19229332 Curated Info |
|
Hiragami-Hamada K, et al. (2009) The molecular basis for stability of heterochromatin-mediated silencing in mammals. Epigenetics Chromatin 2, 14
19889207 Curated Info |
|
Dryhurst D, et al. (2009) Characterization of the histone H2A.Z-1 and H2A.Z-2 isoforms in vertebrates. BMC Biol 7, 86
20003410 Curated Info |
|
Possemato A (2008) CST Curation Set: 5684; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2008) CST Curation Set: 5685; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2008) CST Curation Set: 5646; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2008) CST Curation Set: 5649; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/inhibitor; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2008) CST Curation Set: 5647; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/inhibitor; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2008) CST Curation Set: 5648; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/inhibitor; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Kang TJ, Yuzawa S, Suga H (2008) Expression of histone H3 tails with combinatorial lysine modifications under the reprogrammed genetic code for the investigation on epigenetic markers. Chem Biol 15, 1166-74
19022177 Curated Info |
|
Pless O, et al. (2008) G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. J Biol Chem 283, 26357-63
18647749 Curated Info |
|
Possemato A (2008) CST Curation Set: 5212; Year: 2008; Biosample/Treatment: cell line, HCT116/TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2008) CST Curation Set: 5213; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4814; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4815; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4816; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4817; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4810; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4811; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4812; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4813; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4806; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4807; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4808; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4809; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Kapoor-Vazirani P, Kagey JD, Powell DR, Vertino PM (2008) Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res 68, 6810-21
18701507 Curated Info |
|
Possemato A (2008) CST Curation Set: 4822; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2008) CST Curation Set: 4823; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2008) CST Curation Set: 4802; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4804; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4805; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4800; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4801; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4798; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4799; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4757; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4758; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4767; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4768; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4755; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4797; Year: 2008; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Park YS, et al. (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15, 1968-76
18470569 Curated Info |
|
Li Y (2008) CST Curation Set: 4796; Year: 2008; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4642; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4643; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4644; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4645; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4646; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4647; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Winter S, Fischle W, Seiser C (2008) Modulation of 14-3-3 interaction with phosphorylated histone H3 by combinatorial modification patterns. Cell Cycle 7, 1336-42
18418070 Curated Info |
|
Wiencke JK, Zheng S, Morrison Z, Yeh RF (2008) Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 27, 2412-21
17968314 Curated Info |
|
McGee SL, et al. (2008) AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 57, 860-7
18184930 Curated Info |
|
Li Y (2008) CST Curation Set: 4227; Year: 2008; Biosample/Treatment: cell line, HCT116/SAHA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 4228; Year: 2008; Biosample/Treatment: cell line, HCT116/LCMS75; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Ellis DJ, Lawman ZK, Bonham K (2008) Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem Biophys Res Commun 367, 656-62
18179771 Curated Info |
|
Warnock LJ, Adamson R, Lynch CJ, Milner J (2008) Crosstalk between site-specific modifications on p53 and histone H3. Oncogene 27, 1639-44
17891183 Curated Info |
|
Al-Mahdawi S, et al. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17, 735-46
18045775 Curated Info |
|
Li Y (2008) CST Curation Set: 3783; Year: 2008; Biosample/Treatment: cell line, MM/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 3784; Year: 2008; Biosample/Treatment: cell line, MM/SAHA; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 3785; Year: 2008; Biosample/Treatment: cell line, MM/maz1584; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Shimada M, et al. (2008) Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 132, 221-32
18243098 Curated Info |
|
Li Y (2008) CST Curation Set: 3754; Year: 2008; Biosample/Treatment: cell line, HCT116/SAHA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2008) CST Curation Set: 3755; Year: 2008; Biosample/Treatment: cell line, HCT116/LCMS75; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Aoyama T, et al. (2008) Cell-specific epigenetic regulation of ChM-I gene expression: crosstalk between DNA methylation and histone acetylation. Biochem Biophys Res Commun 365, 124-30
17980151 Curated Info |
|
Metzger E, et al. (2008) Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 10, 53-60
18066052 Curated Info |
|
To KK, et al. (2008) Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 6, 151-64
18234970 Curated Info |
|
Martinato F, Cesaroni M, Amati B, Guccione E (2008) Analysis of Myc-induced histone modifications on target chromatin. PLoS One 3, e3650
18985155 Curated Info |
|
Zhu N, Hansen U (2007) HMGN1 modulates estrogen-mediated transcriptional activation through interactions with specific DNA-binding transcription factors. Mol Cell Biol 27, 8859-73
17938209 Curated Info |
|
Rikova K (2007) CST Curation Set: 3511; Year: 2007; Biosample/Treatment: cell line, 786-0 vector/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2007) CST Curation Set: 3513; Year: 2007; Biosample/Treatment: cell line, 786-0 VHL-30/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2007) CST Curation Set: 3515; Year: 2007; Biosample/Treatment: cell line, UOK-101/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Rikova K (2007) CST Curation Set: 3517; Year: 2007; Biosample/Treatment: cell line, UOK-101/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2007) CST Curation Set: 3506; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2007) CST Curation Set: 3507; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2007) CST Curation Set: 3508; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2007) CST Curation Set: 3509; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2007) CST Curation Set: 3510; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Stokes M (2007) CST Curation Set: 3465; Year: 2007; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Dai B, Rasmussen TP (2007) Global epiproteomic signatures distinguish embryonic stem cells from differentiated cells. Stem Cells 25, 2567-74
17641388 Curated Info |
|
Possemato A (2007) CST Curation Set: 3231; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 3232; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Sun H, et al. (2007) Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. Biochem Biophys Res Commun 358, 435-41
17498659 Curated Info |
|
Possemato A (2007) CST Curation Set: 2992; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2994; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2995; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2996; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2997; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2998; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2007) CST Curation Set: 2999; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Koch CM, et al. (2007) The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res 17, 691-707
17567990 Curated Info |
|
Lin T, et al. (2007) Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. Surgery 141, 784-94
17560255 Curated Info |
|
Possemato A (2007) CST Curation Set: 2865; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Cherry J (2007) CST Curation Set: 2821; Year: 2007; Biosample/Treatment: cell line, Reh/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2826; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2789; Year: 2007; Biosample/Treatment: cell line, Nomo-1/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2792; Year: 2007; Biosample/Treatment: cell line, MV4-11/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2793; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA 3h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2794; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA 6h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2726; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2730; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/SAHA 3h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2731; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2735; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2007) CST Curation Set: 2737; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2727; Year: 2007; Biosample/Treatment: cell line, KMS-18/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2729; Year: 2007; Biosample/Treatment: cell line, KMS-18/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2707; Year: 2007; Biosample/Treatment: cell line, Reh/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2708; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2709; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2710; Year: 2007; Biosample/Treatment: cell line, SEM/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2711; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2712; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2007) CST Curation Set: 2694; Year: 2007; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2007) CST Curation Set: 2698; Year: 2007; Biosample/Treatment: cell line, HCT116/untreated &'||' nicotinamide; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Farnsworth C (2007) CST Curation Set: 2671; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
comb b (2007) CST Curation Set: 2621; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
comb b (2007) CST Curation Set: 2623; Year: 2007; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
comb b (2007) CST Curation Set: 2624; Year: 2007; Biosample/Treatment: cell line, MKN-45/untreated &'||' TSA; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Garcia BA, et al. (2007) Organismal differences in post-translational modifications in histones H3 and H4. J Biol Chem 282, 7641-55
17194708 Curated Info |
|
Cherry J (2007) CST Curation Set: 2509; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2511; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2512; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2514; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2472; Year: 2007; Biosample/Treatment: cell line, Nomo-1/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2473; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA 3h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2477; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA 6h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2436; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2438; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2439; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2440; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2441; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Appanah R, et al. (2007) An unmethylated 3' promoter-proximal region is required for efficient transcription initiation. PLoS Genet 3, e27
17305432 Curated Info |
|
Possemato A (2007) CST Curation Set: 2412; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2007) CST Curation Set: 2413; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Li Y (2007) CST Curation Set: 2374; Year: 2007; Biosample/Treatment: cell line, HT-29/untreated &'||' nicotinamide; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2336; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2337; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2007) CST Curation Set: 2343; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2007) CST Curation Set: 2344; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Cherry J (2007) CST Curation Set: 2312; Year: 2007; Biosample/Treatment: cell line, MV4-11/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2007) CST Curation Set: 2316; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2007) CST Curation Set: 2292; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2007) CST Curation Set: 2293; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2007) CST Curation Set: 2287; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2007) CST Curation Set: 2288; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2007) CST Curation Set: 2289; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2007) CST Curation Set: 2290; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Moritz A (2007) CST Curation Set: 2291; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info |
|
Possemato A (2006) CST Curation Set: 2192; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2006) CST Curation Set: 2193; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2006) CST Curation Set: 2194; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2006) CST Curation Set: 2195; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2006) CST Curation Set: 2187; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 2117; Year: 2006; Biosample/Treatment: cell line, SW620/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2029; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2030; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2032; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2033; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2034; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2035; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Cherry J (2006) CST Curation Set: 2036; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1998; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1999; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 2000; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1971; Year: 2006; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1972; Year: 2006; Biosample/Treatment: cell line, SW480/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1973; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1974; Year: 2006; Biosample/Treatment: cell line, SW620/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Moritz A (2006) CST Curation Set: 1968; Year: 2006; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Guo A (2006) CST Curation Set: 1852; Year: 2006; Biosample1/Treatment/Isotope: cell line, NCI-H3255/TSA 6h/L, Biosample2/Treatment/Isotope: cell line, NCI-H3255/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Guo A (2006) CST Curation Set: 1853; Year: 2006; Biosample1/Treatment/Isotope: cell line, NCI-H3255/TSA 24h/L, Biosample2/Treatment/Isotope: cell line, NCI-H3255/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Guo A (2006) CST Curation Set: 1854; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCC78/TSA 6h/L, Biosample2/Treatment/Isotope: cell line, HCC78/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Guo A (2006) CST Curation Set: 1855; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCC78/TSA 24h/L, Biosample2/Treatment/Isotope: cell line, HCC78/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2006) CST Curation Set: 1807; Year: 2006; Biosample/Treatment: cell line, HCC827/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Possemato A (2006) CST Curation Set: 1808; Year: 2006; Biosample/Treatment: cell line, HCC78/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1810; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCT116/serum starved &'||' EGF/L, Biosample2/Treatment/Isotope: cell line, HCT116/serum starved/serum starved/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Kim SC, et al. (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23, 607-18
16916647 Curated Info |
|
Li Y (2006) CST Curation Set: 1632; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Li Y (2006) CST Curation Set: 1564; Year: 2006; Biosample/Treatment: cell line, SW48/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Li Y (2006) CST Curation Set: 1567; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Beck HC, et al. (2006) Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics 5, 1314-25
16627869 Curated Info |
|
Miao F, et al. (2006) Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. Mol Endocrinol 20, 1562-73
16497732 Curated Info |
|
Espino PS, et al. (2006) Chromatin modification of the trefoil factor 1 gene in human breast cancer cells by the Ras/mitogen-activated protein kinase pathway. Cancer Res 66, 4610-6
16651411 Curated Info |
|
Guo A (2006) CST Curation Set: 1208; Year: 2006; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Guo A (2006) CST Curation Set: 1209; Year: 2006; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Mitchell J (2006) CST Curation Set: 1210; Year: 2006; Biosample/Treatment: cell line, NCI-H520/serum starved; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Mitchell J (2006) CST Curation Set: 1211; Year: 2006; Biosample/Treatment: cell line, NCI-H520/serum starved; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Mitchell J (2006) CST Curation Set: 1213; Year: 2006; Biosample/Treatment: cell line, NCI-H23/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Thomas CE, Kelleher NL, Mizzen CA (2006) Mass spectrometric characterization of human histone H3: a bird's eye view. J Proteome Res 5, 240-7
16457588 Curated Info |
|
Li Y (2006) CST Curation Set: 1101; Year: 2006; Biosample/Treatment: cell line, SW480/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Li Y (2006) CST Curation Set: 1103; Year: 2006; Biosample/Treatment: cell line, SW620/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Hake SB, et al. (2006) Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J Biol Chem 281, 559-68
16267050 Curated Info |
|
Forneris F, et al. (2005) Human histone demethylase LSD1 reads the histone code. J Biol Chem 280, 41360-5
16223729 Curated Info |
|
Mitchell J (2005) CST Curation Set: 1018; Year: 2005; Biosample/Treatment: cell line, HepG2/-; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Mitchell J (2005) CST Curation Set: 1019; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA &'||' nicotinamide; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Gu T (2005) CST Curation Set: 957; Year: 2005; Biosample/Treatment: cell line, OCI/AML2/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Gu T (2005) CST Curation Set: 958; Year: 2005; Biosample/Treatment: cell line, OCI/AML3/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Huang W, et al. (2005) Increases in intracellular calcium dephosphorylate histone H3 at serine 10 in human hepatoma cells: potential role of protein phosphatase 2A-protein kinase CbetaII complex. J Cell Physiol 205, 37-46
15880462 Curated Info |
|
Mitchell J (2005) CST Curation Set: 867; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Mitchell J (2005) CST Curation Set: 868; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info |
|
Guo A (2005) CST Curation Set: 762; Year: 2005; Biosample/Treatment: cell line, HeLa/TSA; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info |
|
Ananthanarayanan M, et al. (2004) Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1. J Biol Chem 279, 54348-57
15471871 Curated Info |
|
Pal S, et al. (2004) Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 24, 9630-45
15485929 Curated Info |
|
Bronder JL, Moran RG (2003) A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem 278, 48861-71
14517211 Curated Info |
|
Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23, 206-15
12482974 Curated Info |
|
Edmondson DG, et al. (2002) Site-specific loss of acetylation upon phosphorylation of histone H3. J Biol Chem 277, 29496-502
12039950 Curated Info |